K

Kyverna Therapeutics
D

KYTX

7.34000
USD
-0.30
(-3.93%)
مغلق
حجم التداول
54,784
الربح لكل سهم
-3
العائد الربحي
-
P/E
-3
حجم السوق
453,930,879
المقالات
المزيد

العنوان: Kyverna Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.